The Middle East & Africa organ preservation solution market was valued at US$ 10,070.97 thousand in 2023 and is expected to reach US$ 13,892.13 thousand by 2031; it is estimated to register a CAGR of 4.1% from 2023 to 2031.
The machine perfusion technique involves continuously providing artificial perfusion to the blood vessels of a grafted organ. This helps actively control the temperature, partial oxygen pressure, chemical composition, and mechanical stress of the internal environment of the organ. Machine perfusion is an advanced technology involving organ perfusion with a controlled perfusion flow. This method helps maintain the organ's microvasculature, provide oxygen and nutrients to support tissue metabolism, and remove toxic metabolic waste. Ex-vivo machine perfusion devices have been studied for their function in various temperature conditions, e.g., normothermic machine perfusion (NMP) at 35–38°C, subnormothermic machine perfusion (SNMP) at 20–34°C, controlled oxygenated rewarming (COR) at 8–20°C, and hypothermic machine perfusion (HMP) at 0–8°C.
The success of organ preservation using dynamic machine perfusion, which operates with blood-based perfusates at close-to-physiological temperatures, has encouraged more in-depth studies on organ preservation and repair/reconditioning. Prolonged machine perfusion outside the body allows organ repair and reprogramming, necessitating the further exploration of new strategies to enhance the quality of donor grafts before transplantation. This technology has shown clinical efficacy in kidney, liver, and lung transplantation. In liver transplantation, machine perfusion reduces ischemia-reperfusion injury (I/R injury), protects the endothelium, prevents biliary complications, and assesses graft viability before transplantation. The time of machine perfusion outside the body can be extended by optimizing current perfusates by adding essential components such as amino acids to meet metabolic needs. Therefore, the shift toward the machine perfusion technique is expected to emerge as a new trend in the organ preservation solution market soon.
The Middle East & Africa organ preservation solution market is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of MEA. The market is expected to rise due to growth opportunities in countries, increasing investments in the development of the healthcare industry, and several government initiatives. According to a recent report by the Gulf Cooperation Council (GCC), GCC countries made the world's most prominent investments in healthcare infrastructure during 2010–2020. The incidence of diabetes is increasing rapidly in Saudi Arabia. It is expected to remain consistently high in the coming years due to the presence of a high percentage of obese and overweight citizens. According to the World Health Organization (WHO), children from Saudi Arabia are more likely to develop diabetes at an early age due to an unhealthy lifestyle and insufficient physical activity. The prevalence of juvenile diabetes has also been observed to be increasing continuously in the country in recent years. According to a report by the International Diabetes Federation (IDF), 10% of people from Saudi Arabia suffer from diabetes, and the prevalence will almost double by 2045. Furthermore, ~4.27 million Saudi Arabians have diabetes, and 1.86 million are yet to be diagnosed with the disease. Diabetes cases are expected to reach 5.6 million and 7.5 million by 2030 and 2045, respectively. Over time, diabetes can lead to kidney disease and kidney failure, propelling the requirement for a kidney transplant. Thus, rising cases of diabetes bolster the organ preservation solution market growth in Saudi Arabia.
In May 2024, the Saudi Center for Organ Transplantation completed the integration process with the Tawakkalna app. This step aims to increase awareness about organ donation and encourage community members to register as organ donors after death. The initiative is a part of the center's digital transformation journey. It aims to automate processes, improve user experience, and provide services more efficiently and conveniently, aligning with the objectives of Saudi Arabia's Vision 2030.
The Middle East & Africa organ preservation solution market is categorized into product, application, type, end user, and country.
Based on product, the Middle East & Africa organ preservation solution market is categorized into University of Wisconsin solution, custodiol HTK, Perfadex, Hypothermosol, and others. The University of Wisconsin segment held the largest market share in 2023.
In terms of application, the Middle East & Africa organ preservation solution market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held the largest market share in 2023.
By type, the Middle East & Africa organ preservation solution market is categorized into kidneys, liver, lungs, heart, and others. The kidneys segment held the largest market share in 2023.
Based on end user, the Middle East & Africa organ preservation solution market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment held the largest market share in 2023.
By country, the Middle East & Africa organ preservation solution market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa organ preservation solution market share in 2023.
XVIVO Perfusion, TransMedics, Dr. Franz Koehler Chemie GmbH, and Accord Healthcare, are among the leading companies operating in the Middle East & Africa organ preservation solution market.